View clinical trials related to Hematologic Disease.
Filter by:The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.
The purpose of the study is to determine whether oral contraceptives, desmopressin acetate, and/or tranexamic acid are effective in the treatment of women with menorrhagia who are diagnosed with a bleeding disorder.
Diamond Blackfan anemia (DBA) is a condition in which the bone marrow is underdeveloped. DBA is considered a congenital disease, meaning patients are born with it. In DBA there is a lack of cells that give rise to red blood cells. The other elements produced in the bone marrow, such as white blood cells and platelets, are normal. Standard treatments used for this disorder such as steroids and bone marrow transplants are associated with failure, relapse, side-effects, increased morbidity, and even death. Two drugs, antithymocyte globulin (ATG) and cyclosporin have been used to treat DBA, but have only provided occasional responses. No study has ever combined these two drugs for the treatment of DBA. This study is designed to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of DBA.
The Hematology Service provides hematology consultations for patients at the Clinical Center and participates in the training of hematology fellows. Patients with a broad range of hematologic disorders must be available in order for the senior staff of the Service to maintain clinical expertise and to provide the breadth of experience necessary for the fellowship program. The purpose of this protocol is to meet these needs by allowing the Hematology Service to see patients with a spectrum of hematologic diseases not studied on existing research protocols at the NIH. These patients will be evaluated over the course of several outpatient visits and returned to the care of their referring physicians.This study was developed to evaluate and possibly treat patients with blood disorders. The Hematology Service of the National Institutes of Health is responsible for the care of patients participating in research studies. In addition the Hematology Service also provides consultation for small groups of patients with blood disorders that have not been diagnosed or that may need special testing. This study will also provide doctors at the NIH the opportunity to learn more about a wide range of blood disorders and conditions. Patients participating in this study will be evaluated over the course of several outpatient visits and will continue to be cared for by their regular physician.